ST. LOUIS — The National Institutes of Health released early results on of a trial involving Washington University, showing that two anti-inflammatory drugs reduced the risk of death in patients with severe COVID-19.
The researchers will soon release the findings in a preprint and aim to publish in a peer-reviewed journal this fall, but the NIH released the initial findings on Thursday.
The trial included patients hospitalized with moderate to severe cases. The 518 patients who received the drug infliximab had a mortality rate of 10%, compared with 14.5% in the placebo group. The 509 patients who received the drug abatacept had a mortality rate of 11%, compared with 15% in the placebo group.
